北京市1992-2013年乙型肝炎疫苗免疫接种预防乙型肝炎肝硬化的成本-效益
|
摘要
目的评估北京市1992-2013年乙型肝炎(乙肝)疫苗(Hepatitis B vaccine,HepB)接种预防乙肝肝硬化的效益-成本比(Benefit-cost ratio,BCR)。方法采用成本效益法测算1992-1993年北京市HepB接种成本、乙肝肝硬化花费和效益值,分析BCR。结果 1992-2013年北京市HepB免疫接种总成本为13 419.42万元,HepB接种为预防乙肝肝硬化带来的总效益为115 205.46万元,BCR为8.58。结论北京市HepB免疫接种对预防乙肝肝硬化具有较高的BCR。
Objective To estimate the benefit-cost ratio(BCR) of hepatitis B vaccine(HepB) vaccination for preventing hepatitis B related cirrhosis in Beijing during 1992-2013. Methods We used cost-benefit analysis to measure costs of HepB vaccination and expenses and benefits of preventing hepatitis B related cirrhosis to estimate a benefit-cost ratio(BCR). Results During 1992-2013, the total cost of HepB vaccination in Beijing was 134 194.2 thousand RMB. HepB vaccination produced a benefit of 1 152 054.6 thousand RMB in preventing hepatitis B related cirrhosis. The BCR of HepB vaccination was 8.58 for cirrhosis prevention. Conclusions HepB vaccination showed a high BCR in preventing hepatitis B related cirrhosis.
Objective To estimate the benefit-cost ratio(BCR) of hepatitis B vaccine(HepB) vaccination for preventing hepatitis B related cirrhosis in Beijing during 1992-2013. Methods We used cost-benefit analysis to measure costs of HepB vaccination and expenses and benefits of preventing hepatitis B related cirrhosis to estimate a benefit-cost ratio(BCR). Results During 1992-2013, the total cost of HepB vaccination in Beijing was 134 194.2 thousand RMB. HepB vaccination produced a benefit of 1 152 054.6 thousand RMB in preventing hepatitis B related cirrhosis. The BCR of HepB vaccination was 8.58 for cirrhosis prevention. Conclusions HepB vaccination showed a high BCR in preventing hepatitis B related cirrhosis.
引文
[1]周福生.肝病中医临证旨要[M].第1版.广东:广东科技出版社, 2010:219.ZHOU FS. Liver disease from the perspective of traditional Chinese medicine[M]. 1st edition. Guangdong:Guangdong Science and Technology Press, 2010:219.
[2]余海蓉,赵羚谷.降低肝硬化发病预防乙肝最关键[N].深圳特区报, 2006-07-09(A05).YU HR. To reduce the morbidity of liver cirrhosis, the key is to prevent hepatitis B[N]. Shenzhen Special Zone Daily,2006-07-08(A05).
[3] LIANG XF, BI SL, YANG WZ, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China[J]. The Journal of Infectious Diseases, 2009, 200(1):39-47.
[4]杨志勇.北京市海淀区肝炎疫苗干预的经济评价研究[D].沈阳:中国医科大学, 2007.YANG ZY. Economic evaluation of viral hepatitis vaccine interference in Haidian district of Beijing[D]. Shenyang:China Medical University, 2007.
[5]卢亮平,李辉,邢丽丽,等.高剂量乙肝疫苗免疫策略成本效益分析[J].中国公共卫生, 2002, 21(1):31-32.LU LP, L H, X LL, et al. Cost-benefit analysis of high-dose immunization strategy of infant hepatitis B vaccination[J].Chinese Journal of Public Health, 2002, 21(1):31-32.
[6]倪红霞.乙肝病毒母婴传播的病毒变异规律与乙肝疫苗免疫保护效果研究[D].上海:第二军医大学, 2013.NI HX. Regulation of hepatitis B virus muta t ion and ef f ect of immunoprophylaxis in mother-to-child transmission[D]. Shanghai:the Second Military Medical University, 2013.
[7]夏国良,龚健,王继杰,等.重组乙型肝炎疫苗阻断乙型肝炎病毒母婴传播方案的保护效果评价[J].中华流行病学杂志, 2003, 24(5):362-365.XIA GL, GONG J, WANG J J, et al. Efficacy of recombinant hepatitis B vaccine and low-dose hepatitis B immune globulin in preventing mother-infant transmission of hepatitis B virus infection[J]. Chinese Journal of Epidemiology, 2003, 24(5):362-365.
[8] GRAY AM. Appl ied methods of cost-ef f ect iveness analysis in health care[M]. 1st edition. New York:Oxford University Press, 2011:135-136.
[9]蒋艳,满晓玮,赵丽颖,等.卫生总费用时间序列核算中缺失数据的处理技术[J].中国卫生经济, 2014, 33(4):41-42.JIANG Y, MAN XW, ZHAO LY, et al. The processing techniques for missing data of total health expenditure based on t ime ser ies account ing[J]. Chinese Health Economics, 2014, 33(4):41-42.
[10]于淑丽.乙型肝炎免疫接种策略的评价[D].上海:复旦大学,2003.YU SL. An evaluation of hepatitis B vaccination program strategies[D]. Shanghai:Fudan University, 2003.
[11]党如波,张顺祥,张卫东,等.中国新生儿乙肝疫苗免疫效果评估[J].中国公共卫生, 2009, 25(4):385-387.DANG RB, ZHANG SX, ZHANG WD, et al. Assessment for immune effect iveness of hepatitis B vaccinat ion among infant population in China[J]. Chinese Journal of Public Health, 2009, 25(4):385-387.
[12]马起山.广州市乙肝相关疾病经济负担及1~14岁人群乙肝疫苗接种策略研究[D].广州:广东药学院, 2011.MA QS. Study on the economic burden of hepatitis B related diseases in Guangzhou and the strategies of hepatitis B vaccination for population aged 1~14 in China[D]. Guangdong:Guangdong Pharmaceutical University, 2011.
[13] BOCCALINI S, TADDEI C, CECCHERINI V, e t a l.Economic analysis of the f irst 20 years of universal hepatitis B vaccination program in Italy:a posteriori evaluation and f orecast of f uture benef its[J]. Human Vaccines&Immunotherapeutics, 2013, 9(5):1119-1128.
[14]李俊,孙莲英,曾雪霞,等.海南省新生儿接种乙肝疫苗成本效益分析[J].中国热带医学, 2011, 11(1):18-21.LI J, SUN LY, ZENG XX, et al. Cost-benefit analysis of hepatitis B vaccine inoculation in infants in Hainan[J].China Tropical Medicine, 2011, 11(1):18-21.
[15]耿翠芳,楼映.乙肝疫苗免疫接种的成本效益分析[J].上海医药, 2004, 26(10):471-472.GENG CF, LOU Y. Cost-benef it analysis of hepatitis B immunization[J]. Shanghai Medical&Pharmaceutical Journal, 2004, 26(10):471-472.
[16]吕静静.山东省新生儿乙肝疫苗免疫策略经济学评价研究[D].济南:山东大学, 2013.LV JJ. Economic evaluation of hepatitis B immunization strategy among newborns in Shandong[D]. Jinan:Shandong University, 2013.
[17]马晓华.中国疾控中心:政策应推动疫苗研发[N].第一财经日报, 2011-05-25(A05).MA XH. Chinese Center for Disease Control and Prevention:policy should promote the development of vaccines[N]. China Business News, 2011-05-25(A05).
[18]张培刚,方齐云.厂商理论的新进展[J].经济学动态, 1997,(8):47-51.ZHANG PG, FANG QY. Development in firm theory[J].Economics Information, 1997,(8):47-51.
[19]叶凌,王达特.乙肝疫苗接种效果与成本-效益分析[J].中国药物经济学, 2007,(4):33-36.YE L, WANG DT. Effectiveness and cost-benefit analysis of hepatitis B immunization[J]. China Journal of Pharmaceutical Economics, 2007,(4):33-36.
[2]余海蓉,赵羚谷.降低肝硬化发病预防乙肝最关键[N].深圳特区报, 2006-07-09(A05).YU HR. To reduce the morbidity of liver cirrhosis, the key is to prevent hepatitis B[N]. Shenzhen Special Zone Daily,2006-07-08(A05).
[3] LIANG XF, BI SL, YANG WZ, et al. Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China[J]. The Journal of Infectious Diseases, 2009, 200(1):39-47.
[4]杨志勇.北京市海淀区肝炎疫苗干预的经济评价研究[D].沈阳:中国医科大学, 2007.YANG ZY. Economic evaluation of viral hepatitis vaccine interference in Haidian district of Beijing[D]. Shenyang:China Medical University, 2007.
[5]卢亮平,李辉,邢丽丽,等.高剂量乙肝疫苗免疫策略成本效益分析[J].中国公共卫生, 2002, 21(1):31-32.LU LP, L H, X LL, et al. Cost-benefit analysis of high-dose immunization strategy of infant hepatitis B vaccination[J].Chinese Journal of Public Health, 2002, 21(1):31-32.
[6]倪红霞.乙肝病毒母婴传播的病毒变异规律与乙肝疫苗免疫保护效果研究[D].上海:第二军医大学, 2013.NI HX. Regulation of hepatitis B virus muta t ion and ef f ect of immunoprophylaxis in mother-to-child transmission[D]. Shanghai:the Second Military Medical University, 2013.
[7]夏国良,龚健,王继杰,等.重组乙型肝炎疫苗阻断乙型肝炎病毒母婴传播方案的保护效果评价[J].中华流行病学杂志, 2003, 24(5):362-365.XIA GL, GONG J, WANG J J, et al. Efficacy of recombinant hepatitis B vaccine and low-dose hepatitis B immune globulin in preventing mother-infant transmission of hepatitis B virus infection[J]. Chinese Journal of Epidemiology, 2003, 24(5):362-365.
[8] GRAY AM. Appl ied methods of cost-ef f ect iveness analysis in health care[M]. 1st edition. New York:Oxford University Press, 2011:135-136.
[9]蒋艳,满晓玮,赵丽颖,等.卫生总费用时间序列核算中缺失数据的处理技术[J].中国卫生经济, 2014, 33(4):41-42.JIANG Y, MAN XW, ZHAO LY, et al. The processing techniques for missing data of total health expenditure based on t ime ser ies account ing[J]. Chinese Health Economics, 2014, 33(4):41-42.
[10]于淑丽.乙型肝炎免疫接种策略的评价[D].上海:复旦大学,2003.YU SL. An evaluation of hepatitis B vaccination program strategies[D]. Shanghai:Fudan University, 2003.
[11]党如波,张顺祥,张卫东,等.中国新生儿乙肝疫苗免疫效果评估[J].中国公共卫生, 2009, 25(4):385-387.DANG RB, ZHANG SX, ZHANG WD, et al. Assessment for immune effect iveness of hepatitis B vaccinat ion among infant population in China[J]. Chinese Journal of Public Health, 2009, 25(4):385-387.
[12]马起山.广州市乙肝相关疾病经济负担及1~14岁人群乙肝疫苗接种策略研究[D].广州:广东药学院, 2011.MA QS. Study on the economic burden of hepatitis B related diseases in Guangzhou and the strategies of hepatitis B vaccination for population aged 1~14 in China[D]. Guangdong:Guangdong Pharmaceutical University, 2011.
[13] BOCCALINI S, TADDEI C, CECCHERINI V, e t a l.Economic analysis of the f irst 20 years of universal hepatitis B vaccination program in Italy:a posteriori evaluation and f orecast of f uture benef its[J]. Human Vaccines&Immunotherapeutics, 2013, 9(5):1119-1128.
[14]李俊,孙莲英,曾雪霞,等.海南省新生儿接种乙肝疫苗成本效益分析[J].中国热带医学, 2011, 11(1):18-21.LI J, SUN LY, ZENG XX, et al. Cost-benefit analysis of hepatitis B vaccine inoculation in infants in Hainan[J].China Tropical Medicine, 2011, 11(1):18-21.
[15]耿翠芳,楼映.乙肝疫苗免疫接种的成本效益分析[J].上海医药, 2004, 26(10):471-472.GENG CF, LOU Y. Cost-benef it analysis of hepatitis B immunization[J]. Shanghai Medical&Pharmaceutical Journal, 2004, 26(10):471-472.
[16]吕静静.山东省新生儿乙肝疫苗免疫策略经济学评价研究[D].济南:山东大学, 2013.LV JJ. Economic evaluation of hepatitis B immunization strategy among newborns in Shandong[D]. Jinan:Shandong University, 2013.
[17]马晓华.中国疾控中心:政策应推动疫苗研发[N].第一财经日报, 2011-05-25(A05).MA XH. Chinese Center for Disease Control and Prevention:policy should promote the development of vaccines[N]. China Business News, 2011-05-25(A05).
[18]张培刚,方齐云.厂商理论的新进展[J].经济学动态, 1997,(8):47-51.ZHANG PG, FANG QY. Development in firm theory[J].Economics Information, 1997,(8):47-51.
[19]叶凌,王达特.乙肝疫苗接种效果与成本-效益分析[J].中国药物经济学, 2007,(4):33-36.YE L, WANG DT. Effectiveness and cost-benefit analysis of hepatitis B immunization[J]. China Journal of Pharmaceutical Economics, 2007,(4):33-36.